Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00075959 · ClinicalTrials.gov registry record · Phase 2
Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 600
- Enrollment target
NCT00075959 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 600 participants.
The verdict
NCT00075959, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 600 participants
- Enrollment target
Study Summary
This study will determine if NXY-059 is safe in patients with an acute stroke caused by bleeding in the central nervous system. The primary objective was to assess the safety and tolerability of NXY-059 compared to placebo.
Interventions
- DRUG NXY-059
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2004-08 |
| Est. Completion | 2006-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00075959
The ClinicalTrials.gov registry entry for NCT00075959 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NXY-059 is the first listed.
NCT00075959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00075959 about?
NCT00075959 is a clinical study titled "Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke". This study will determine if NXY-059 is safe in patients with an acute stroke caused by bleeding in the central nervous system. The primary objective was to assess the safety and tolerability of NXY-059 compared to placebo.
What is the current status of trial NCT00075959?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 600 participants. The study started on 2004-08. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00075959?
The interventions under investigation include: NXY-059 (DRUG).
Who is sponsoring clinical trial NCT00075959?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.